Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00459212
Status:
COMPLETED
Last Update Posted:
2015-12-04
First Post:
2007-04-09
Brief Title:
GTI-2040 in Treating Patients With Relapsed Refractory or High-Risk Acute Leukemia High-Grade Myelodysplastic Syndromes or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Untreated Adult Acute Myeloid Leukemia |
| Acute Undifferentiated Leukemia |
| Adult Acute Myeloid Leukemia With 11q23 MLL Abnormalities |
| Adult Acute Myeloid Leukemia With Inv16p13q22 |
| Adult Acute Myeloid Leukemia With t1517q22q12 |
| Adult Acute Myeloid Leukemia With t1616p13q22 |
| Adult Acute Myeloid Leukemia With t821q22q22 |
| Blastic Phase Chronic Myelogenous Leukemia |
| de Novo Myelodysplastic Syndromes |
| Previously Treated Myelodysplastic Syndromes |
| Recurrent Adult Acute Lymphoblastic Leukemia |
| Recurrent Adult Acute Myeloid Leukemia |
| Relapsing Chronic Myelogenous Leukemia |
| Secondary Acute Myeloid Leukemia |
| Secondary Myelodysplastic Syndromes |
| Untreated Adult Acute Lymphoblastic Leukemia |
Keywords: